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AN EXISTING METHOD: THE FEMALE CONDOM
The female condom is the only female-initiated method 
(women instigate use but need co-operation of their partner)
that is known to be safe and effective in reducing the risk of
pregnancy and the transmission of sexually transmitted
infections (STIs). The design of the female condom offers more
protection to women than the male condom because the
outer ring partially covers the external genitalia. Studies in a
variety of countries and cultures show that, on average, 50 -
70% of male and female participants found the female
condom to be acceptable.7 An acceptability study in South
Africa found that 30% of the female participants used the
female condom at least once, and of these 86% said they
would use it again and 95% said they would recommend it to
friends.8
In terms of pregnancy prevention, the female condom is
comparable to the male condom. Twenty-one per cent of
women using the female condom will become pregnant in the
first year of use compared with 15% of male condom users.9
With correct and consistent use, 5% of female condom users
and 2% of male condom users will experience a pregnancy in
the first year of use.  More recent studies in China, Panama
and Nigeria showed higher effectiveness rates of 94 - 98% for
the female condom compared with 92 - 96% for the male
condom.10 Regarding prevention of STIs, a systematic review
found that female condoms confer as much protection from
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Worldwide, nearly 5 million new HIV infections occurred in 2005 with more than 3 million of these in sub-Saharan Africa.
Despite declines in the HIV prevalence in some sub-Saharan African countries, many continue to be heavily affected.1 In
Zimbabwe data have shown a decrease in prevalence from 22.1% to 20.1% since 2003, yet there is no sign of a similar trend
in South Africa, where the adult prevalence rate is 18.8%.2 National-level prevalence rates, however, may not reveal the full
impact of the epidemic on different populations. For example, 30.2% of pregnant women in South Africa attending public
antenatal clinics in 2005 were HIV positive, with rates varying by province from 15.7% in the Western Cape to 39.1% in
KwaZulu-Natal.3 In addition, female youth aged 15 - 24 years were three times more likely to be infected than young men in
the same age group.4
Women are increasingly bearing the burden of the epidemic. Of the 39 million people worldwide living with HIV/AIDS, half are
women. UNAIDS estimates that of the new infections expected to occur between 2002 and 2010, 70% will be among women
in the developing world.5 Several factors account for women’s higher risk of infection, including biological, socio-cultural and
economic factors. For instance, the female reproductive tract is more susceptible to HIV infection than the male reproductive
system, and young women are at highest risk of HIV infection due to an immature physiology. Further, sexual violence and
gender inequalities frequently play a role in women’s and girls’ ability to practise safer sex.6
Current HIV prevention methods are male-initiated or require a male partner’s co-operation, leaving women without sufficient
means to protect themselves from infection. New female-controlled prevention methods are urgently needed to reduce
women’s and girls’ risk of HIV infection. This article provides an update on currently available methods and others being tested
and/or developed to provide women and girls with more HIV prevention options. 
december 2006                                        THE SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE    8
STIs as male condoms.11 In addition, laboratory studies have
demonstrated that the female condom blocks the passage of
microorganisms, including HIV.12
Currently, the only female condom that is approved by the US
Food and Drug Administration and procured by large donor
agencies is the FC Female Condom® produced by the Female
Health Company; two other female condom brands are
marketed outside the USA. The most common complaints
about the female condom – aesthetics, difficulty with
insertion and noise – typically fade with repeated use.
Nevertheless, several new condoms are being developed that
address these concerns and may also be less expensive. The
World Health Organization announced in August that the
second generation FC2 Female Condom, made of nitrile, a
latex derivative, had met international standards for dual
protection against pregnancy and STI/HIV infection and will be
cheaper to produce.13
Since the female condom entered the market in 1992, more
than 100 million have been distributed in more than 90
countries.14 Since the female condom was introduced into the
country in 1998 through a national pilot programme, South
Africa has become the second-largest distributor of female
condoms globally (following Brazil) with procurement of
female condoms growing from 1.3 million in 2002 to 2.4
million in 2005.15 A forthcoming study reports that if 53.7
million female condoms were distributed in South Africa,
32 000 HIV infections would be prevented, which would
translate into cost savings of between $5.3 and $35.7
million.16
There also have been several recent efforts to scale up female
condom programmes. In September 2005, a global
consultation was held in the USA to develop a plan of action
for garnering international support for the female condom.
Also in 2005, the United Nations Population Fund launched
the Global Female Condom Initiative, which aims to scale up
female condom programming in at least 23 countries. Finally,
the recently launched Prevention Now! Campaign is working
to promote universal access to female condoms and other
existing STI/HIV prevention options. 
PROMISING NEW METHODS UNDER DEVELOPMENT:
MICROBICIDES
Microbicides are substances designed to reduce transmission
of HIV and/or other STIs when applied vaginally and will
probably come in a variety of forms including gels, creams,
films, suppositories and vaginal rings. Although not yet
available, microbicides are a promising female-controlled
method that have been under development for the past 15
years. Microbicides could work by:
■ Boosting the body’s natural defenses against infection
(vaginal defense enhancer)
■ Damaging the surface membranes of pathogens rendering
them ineffective (surfactant)
■ Binding to a pathogen or healthy cell to prevent
attachment by an infectious agent (entry and fusion
inhibitor), and/or 
■ Incorporating antiretrovirals which could work by
preventing viruses from replicating in a cell (replication
inhibitors).
Currently there are 12 candidate microbicides in clinical
evaluation with 4 in large advanced studies (Table I).17 The
earliest results are expected in 2008. South Africa serves as a
clinical research site for all 4 of the microbicide candidates
currently in late-stage trials for HIV prevention.18
Because of their different modes of action, some microbicides
are designed to reduce the risk of pregnancy and STIs,
including HIV, while others aim only to prevent infection,
enabling women who want to conceive to protect themselves
from disease. 
It is estimated that the first microbicides will be 50 - 60%
effective in preventing HIV – much lower than the
approximate 90% effectiveness rate of male condoms.19
However, microbicides offer an important alternative in those
situations when male condom use is impossible. For example,
if only 20% of people at risk of HIV use a microbicide that is
60% effective in protecting against HIV transmission, 2.5
million infections could be averted over 3 years.20
More than 60 studies have been conducted in developed and
developing countries to determine the characteristics of an
acceptable microbicide. Interest in microbicides is higher in
areas where women perceive their HIV risk to be greater. In
addition, these studies indicate the need for a variety of
products to meet the range of demands of a diverse consumer
population. In South Africa, qualitative research revealed
support for microbicides stemming from respondents’
concerns around the HIV epidemic, rape, sexual coercion and
unplanned consensual sex.21
Microbicides have garnered much greater attention in the past
few years. After the record-level attendance for the
Microbicides 2006 conference in Cape Town, South Africa,
microbicides again took centre stage at the recent XVI
International AIDS Conference in Toronto, Canada. Bill Gates
opened the conference by stating, ‘We need to put the power
to prevent HIV in the hands of women.’
Mechanism Candidate
of action product Developer Phase
Vaginal defense
enhancers BufferGel® ReProtect, Inc. Phase 2/2B




(CS) CONRAD Phase 3
PRO 2000 Indevus Phase 3
Pharmaceuticals, 
Inc.
*Adapted from the Alliance for Microbicide Development.
TABLE I. MICROBICIDES IN ADVANCED CLINICAL TRIALS*
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Greater attention and advocacy has increased funding for
microbicide research and development with annual global
investment rising from US $65 million in 2000 to US $163
million committed for 2005.17 Public-private partnerships have
played a critical role in advancing microbicide research.
Commercial investment has been sorely lacking, while funding
from national level sources is increasing. Experts agree that
despite increased investment a global funding shortfall
remains and that US $280 million is needed on an annual
basis.
NEW POTENTIAL OF OLD METHODS: CERVICAL
BARRIERS
For thousands of years women have used various forms of 
cervical barriers for reproductive health purposes. For
example, the contraceptive diaphragm was developed in the
late 19th century and by 1930 was the most frequently
prescribed contraceptive method in the USA. Diaphragms and
cervical caps were also popular contraceptives in the early
1900s in Europe, including Holland, Germany, England and
France.22
Cervical barrier methods when used with spermicide have
proven contraceptive benefits. However, internationally few
women rely on cervical barrier methods for contraception.
According to the United Nations Population Division, only
0.5% of women (married or in partnerships currently using
contraception) aged 15 - 49 years use vaginal barrier methods,
including the diaphragm, cervical cap and spermicidal foams,
jelly, cream and sponges (see Fig. 1 for worldwide use).
Historically, cervical barrier use has been limited in much of
Africa partly owing to the lack of providers trained to counsel
clients on use and to fit vaginal devices. Providers may also
shy away from offering cervical barriers because of the need
to clean and sterilise devices used for fitting.23 Misperceptions
about cervical barriers and lack of knowledge about these
products as well as provider bias towards other methods may
limit support for use of cervical barriers. Some providers in a
three-country study perceived appropriate candidates for the
diaphragm to be educated and ‘open-minded’ women;
however, attitudes toward the diaphragm changed following
provider training.24 Newer, more effective pregnancy
prevention methods, such as hormonal contraception, have
also led to a decline in interest in cervical barriers in Africa and
other parts of the world.
Several acceptability studies have been conducted in a range
of developing countries including Egypt,25 Turkey,26,24
Colombia,24 the Philipines,24 Brazil,27 Zimbabwe28 and India.29
These studies show that diaphragms are generally well
accepted, particularly if women receive counselling from
providers and support from their partners. In India,
researchers reported that even in the absence of privacy or a
bathroom at home, women were capable of using the
diaphragm successfully.29 Findings from a recent study
conducted in Johannesburg, South Africa, showed that 78% of
participants were willing to try microbicides while 60% and
56%, respectively, were willing to use the diaphragm and the
female condom.30
Although the diaphragm was previously available in South
Africa, it is not currently available in either the private or the
public health care sector. Despite this lack of availability,
16.4% of all women surveyed in the 1998 Demographic and
Health Survey had knowledge of the diaphragm as a
contraceptive method and 0.8% of women had ever used the
method. Among women currently using contraception,
unsurprisingly, none reported use of the diaphragm.31
Although not yet proven, cervical barriers may also provide
some protection against HIV and STIs. Prior observational
studies indicate that women who used a diaphragm with
spermicide had a reduced risk of acquiring STIs and associated
long-term sequelae.32 All of the studies compared diaphragm
users with non-users, and all used some type of multivariate
analysis to control for known co-factors or confounders such
as socioeconomic status or age. Because these studies were
not designed to test the efficacy of the diaphragm, and
because they are all observational studies and therefore
subject to biases, their results must be considered as
suggestive rather than definitive. Clinical trials are currently
underway to investigate whether the diaphragm may reduce
STI/HIV transmission. 
Indeed, there is biological plausibility that the diaphragm may
also decrease risk of HIV acquisition. Several characteristics of
the cervix may mean it is more vulnerable to STIs/HIV than
other areas of the female reproductive tract. First, recent
evidence suggests that the cervix has a high concentration of
Fig. 1. Percentage of women* using vaginal barrier methods†
worldwide, United Nations Population Division 2003.
(*Married or in-union women of reproductive age currently
using contraception. †Diaphragm, cervical cap, spermicidal
foams, jelly, cream and sponges.)
The diaphragm.
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HIV-susceptible cells, resulting in a heightened vulnerability to
HIV infection.33 Second, compared with the thicker cell lining
of the vagina, the cervix is more fragile, covered only by a
single layer of cells. It is therefore biologically more
susceptible to trauma, and therefore STI/HIV infection, than
the vagina. Third, research shows that the cervix is the
preferential infection site for many STIs, including gonorrhoea,
chlamydia, and human papillomavirus (HPV),34,35 and the
presence of STIs increases HIV transmission risk and vice
versa.36 Finally, the cervix is the entryway to the upper genital
tract, which may also be an important site for HIV infection.
Demonstrating the increased activity and interest in cervical
barrier methods, the Microbicides 2006 conference featured
nearly 30 presentations reporting on research aiming to
determine the safety and acceptability of diaphragms and
other cervical barriers as potential STI/HIV prevention
methods. For example, one study among US women found
that two candidate microbicides, Acidform™ and BufferGel®
were safe when used with a diaphragm. In addition,
researchers at the University of California, San Francisco and
University of Zimbabwe found that Cellulose Sulfate gel,
another potential microbicide, when used with the diaphragm
was shown to be safe. Another research trial demonstrated
that the BufferGel Duet™, a cervical barrier that is combined
with the candidate microbicide BufferGel®, was easy to insert
and remove, validating the idea that a cervical barrier can be
prepackaged with a microbicide. One of the most exciting
pieces of news were the results presented by the University of
Pennsylvania showing that BufferGel™ used with the
diaphragm is as effective as the diaphragm used with
nonoxynol-9 (N-9) spermicide for contraception. Having an
N-9 alternative is a significant advance, because N-9 is not
recommended for women at high risk of HIV.
For more information on research and issues related to
cervical barriers, visit the Cervical Barrier Advancement Society
(CBAS) website at www.cervicalbarriers.org.
CONCLUSION
Although female-controlled HIV prevention methods cannot 
address the root causes of women’s vulnerabilities, they will
provide women with more alternatives to protect themselves
from infection. No one method will be right for every woman
or girl, but reproductive health and rights are advanced by
putting the tools of prevention in women’s hands. Because
health care providers are at the forefront in the fight against
HIV, they play a key role in educating clients about available
options, such as the female condom, staying informed about
the development of new promising methods such as
microbicides and cervical barriers, and supporting women in
their method choice. 
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